AMGN · News · 20260908N

Lp(a) Drug Pipeline Risk

AMGEN INC · 2026-09-08 · Importance 37 · Surprise 42

Novartis's Phase III pelacarsen trial lowered lipoprotein(a), but failed to reduce cardiovascular events, raising questions about the efficacy of the broader Lp(a)-lowering drug class. The setback directly affects Amgen's investigational olpasiran, which is being developed to lower Lp(a), as well as rival programs from Eli Lilly and Silence Therapeutics. Investors and analysts questioned whether Lp(a) reduction will translate into cardiovascular-event benefits, creating material uncertainty for Amgen's future cardiovascular pipeline.

Key facts